Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial -

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Cardiovascular system disorders | Obstetrics and gynaecology
Summary
Study in India (n=894) reports all oral antihypertensives reduced systolic blood pressure to 120–150 mm Hg & diastolic blood pressure to 70–100 mm Hg in most women and all three oral drugs are viable initial options for treating severe hypertension in low-resource settings.
UKMi comment
The primary outcome was blood pressure control (defined as 120–150 mm Hg systolic blood pressure and 70–100 mm Hg diastolic blood pressure) within 6 h with no adverse outcomes. The primary outcome was significantly more common in women in the nifedipine group than in those in the methyldopa group (249 [84%] women vs 230 [76%] women; p=0.03). However, the primary outcome did not differ between the nifedipine and labetalol groups (249 [84%] women vs 228 [77%] women; p=0.05) or the labetalol and methyldopa groups (p=0.80).
Related links: